This year, revolutionary anti-obesity drugs Wegovy and Ozempic (manufactured by Danish drugmaker Novo Nordisk), and Eli Lilly ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a ...

Registered dietitian nutritionists caring for patients with chronic kidney disease are frequently challenged to help address ...

Navigating the world of nutrition can feel like trying to find your way through a maze of myths and misconceptions. Before ...

Carrying excess weight places significant strain on the cardiovascular system, increasing risks of life-threatening conditions like stroke and heart attack.

Ozempic is a brand name semaglutide, a medication used to treat type 2 diabetes. It’s also used as an off-label use for weight loss. Wegovy is another brand name with the same a ...

Metabolic healthcare—encompassing conditions such as diabetes, obesity, and hypertension—has become a global health crisis.

Those in the jab trials, however, kept off between 10 and 25 per cent of their body weight over the same timeframe, depending ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...